The Gram-negative bacterium Burkholderia mallei causes rapidly fatal illness in equines and humans when contracted by inhalation and also has the potential to be used as a bioweapon. However, little is known regarding the early innate immune responses and signaling mechanisms required to generate protection from pneumonic B. mallei infection. We showed previously that monocyte chemoattractant protein 1 (MCP-1) was a critical chemokine required for protection from pneumonic B. mallei infection. We have now extended those studies to identify key Toll-like receptor (TLR) signaling pathways, effector cells, and cytokines required for protection from respiratory B. mallei infection. We found that MyD88 ؊/؊ mice were highly susceptible to pulmonary challenge with B. mallei and had significantly short survival times, increased bacterial burdens, and severe organ pathology compared to wild-type mice. Notably, MyD88 ؊/؊ mice had significantly fewer monocytes and dendritic cells (DCs) in lung tissues and airways than infected wild-type mice despite markedly higher bacterial burdens. The MyD88 ؊/؊ mice were also completely unable to produce gamma interferon (IFN-␥) at any time points following infection. In wild-type mice, NK cells were the primary cells producing IFN-␥ in the lungs following B. mallei infection, while DCs and monocytes were the primary cellular sources of interleukin-12 (IL-12) production. Treatment with recombinant IFN-␥ (rIFN-␥) was able to significantly restore protective immunity in MyD88 ؊/؊ mice. Thus, we conclude that the MyD88-dependent recruitment of inflammatory monocytes and DCs to the lungs and the local production of IL-12, followed by NK cell production of IFN-␥, are the key initial cellular responses required for early protection from B. mallei infection.
B
urkholderia mallei, an obligate mammalian pathogen found primarily in equidae, and B. pseudomallei, an opportunistic soil bacterium that infects a wide variety of mammalian species, are both pathogens of mammals (7, 27) . Both organisms have been classified as category B select agents by the Centers for Disease Control and Prevention, and respiratory inoculation with either of these bacteria elicits rapidly fatal pneumonia and sepsis (7, 13, 22, 34) . One unusual feature of Burkholderia infection is that acute infection is rarely fully cleared but often instead results in chronic infection with dissemination to the liver and spleen, which in mice is typically fatal over a period of several months (15, 29) . Other relatively nonpathogenic species of Burkholderia include B. thailandensis and B. cenocepacia, both of which are environmental organisms. The former may cause disease in mice after very-high-dose inoculation (18) , while B. cenocepacia causes infections primarily in humans with altered pulmonary defenses, such as patients with cystic fibrosis (16) .
The role of Toll-like receptor (TLR) signaling in the host defense against Burkholderia infection has been previously examined in a limited number of B. pseudomallei infection studies (33, 36) . TLR2 was shown to actually be detrimental to the host response to B. pseudomallei infection, and similar results were observed following B. thailandensis infection (33, 35) . In contrast, TLR4 was found to be nonessential for protection against B. pseudomallei or B. thailandensis infections, and TLR5 was not essential for protection against respiratory B. thailandensis infection (32, 35) . Nonetheless, mice lacking myeloid differentiation factor 88 (MyD88) are highly susceptible to infection with either B. pseudomallei or B. thailandensis (33, 36) .
Following B. pseudomallei infection, it has been reported that gamma interferon (IFN-␥) production and monocyte recruitment to the lungs were equivalent in wild-type (WT) and MyD88 Ϫ/Ϫ mice (36) . MyD88 Ϫ/Ϫ mice were found to produce less tumor necrosis factor alpha (TNF-␣), CXC ligand 1 (KC), and monocyte chemoattractant protein 1 (MCP-1) than wild-type animals in response to B. pseudomallei infection and were unable to recruit neutrophils to the lungs (36) . Equivalent numbers of monocytes and neutrophils were recruited to the lungs of wildtype and MyD88 Ϫ/Ϫ mice in a B. thailandensis infection model (33) . In contrast, MyD88 Ϫ/Ϫ mice were actually protected against respiratory infection with B. cenocepacia compared to wild-type animals. Thus, there appear to be clear Burkholderia speciesspecific differences in the host innate immune response to infection.
The production of IFN-␥ is critical for protection from infection with B. mallei or B. pseudomallei, and TNF-␣ production is also required for protection from B. pseudomallei infection (1, 23, 24) . We reported recently that MCP-1 (CCL2) played a key protective role in the innate immune responses to acute pulmonary infection with B. mallei (10) . In that report, we found that both CCR2 Ϫ/Ϫ and CCL2 Ϫ/Ϫ mice were highly susceptible to pulmonary challenge with B. mallei. One key finding from those studies was that while the CCR2 Ϫ/Ϫ mice had the expected defects in monocyte recruitment, CCR2 Ϫ/Ϫ animals actually recruited significantly more neutrophils and produced higher concentrations of TNF-␣ than wild-type animals. These findings are in contrast to a previous report suggesting a key protective role for neutrophils in B. pseudomallei infection (8) . Therefore, important differences appear to exist between Burkholderia species with regard to the necessity of MyD88 signaling for protective innate immunity. Since the role of TLR signaling in protection from B. mallei infection has not been previously examined, we used the B. mallei lung infection mouse model to investigate the role of MyD88 and cellular and cytokine responses required to generate early protective pulmonary immunity against this important bacterial pathogen.
MATERIALS AND METHODS
Mice. C57BL/6 mice and TLR2 Ϫ/Ϫ mice on the C57BL/6 background were purchased from Jackson Laboratories (Bar Harbor, ME). To investigate the role of TLR4, the C57BL/10ScNJ strain, which contains a natural deletion of the TLR4 gene, and control strain C57BL/10ScSnJ were used (Jackson Laboratories). MyD88 Ϫ/Ϫ mice on the C57BL/6 background were obtained from Laurel Lenz (National Jewish Medical, Denver, CO) and were bred in-house. All mice used in experiments were 6 to 8 weeks of age at the time of infection, and age-and sex-matched wild-type controls were used for all experiments employing knockout mice. All experiments involving animals were approved by the Institutional Animal Care and Use Committee at Colorado State University.
Bacterial strains and infections. Burkholderia mallei strain ATCC 23344 was used in these studies and was kindly provided by Herbert Schweitzer, Colorado State University. The B. mallei organism used in these studies was initially serially passaged three times in BALB/c mice, and stocks were then prepared and frozen at Ϫ80°C, as described previously (11) . Prior to each challenge study, fresh broth cultures of B. mallei were grown in brucella broth with 4% glycerol (BB4G) (Remel, Lenexa, KS) until bacteria reached the log phase of growth. Titers were determined based on optical density values, and appropriate bacterial dilutions were prepared in sterile phosphate-buffered saline (PBS). Inoculum titers for each experiment were confirmed by plating the inoculum onto BB4G agar plates (Remel).
For intranasal (i.n.) inoculation, mice were anesthetized by intraperitoneal (i.p.) injection with ketamine (100 mg/kg of body weight) (Vedco, Saint Joseph, MO) and xylazine (10 mg/kg) (Ben Venue Labs, Bedford, OH). Mice were infected i.n. with a total volume of 20 l of bacterial inoculum (10 l per nostril). The 50% lethal dose (LD 50 ) following i.n. infection of C57BL/6 mice with B. mallei was previously determined to be 8.4 ϫ 10 2 CFU according to the Reed-Muench method (11, 21) . Mice were infected either with ϳ500 CFU i.n. (ϳ0.5 LD 50 ) or with an experimentally determined LD 100 of 3 ϫ 10 3 CFU (ϳ4 LD 50 ). In experiments where a consistently lethal infection was necessary, mice were infected with 1 ϫ 10 4 CFU i.n. (ϳ10 LD 50 ). All procedures involving B. mallei were performed in a biosafety level 3 (BSL3) facility, in accordance with approved BSL3 and select-agent protocols.
Determination of bacterial burden. At 24, 48, or 72 h after infection, mice were euthanized, and halves of each lung, liver, and spleen were collected separately and placed into 5 ml sterile PBS. Organs were homogenized by using a Stomacher 80 Biomaster instrument (Seward, Bohemia, NY), and supernatants were serially diluted in PBS and plated onto BB4G agar plates (Remel). Agar plates were incubated at 37°C for 48 h, and colonies were counted. The limit of detection for the determination of the bacterial burden in organ homogenates was 100 CFU/organ. For the quantification of bacteremia, heparinized blood was serially diluted in sterile PBS and plated onto BB4G agar plates. The limit of detection for the determination of the bacterial burden in the blood was 10 CFU/ml. Histological analysis. Lungs were inflated with 10% neutral buffered formalin (NBF) (Sigma-Aldrich, St. Louis, MO) via the trachea for 5 min prior to removal and then placed into NBF for 24 h. Livers were collected immediately after euthanasia and placed into NBF for 24 h. After 24 h, organs were transferred into a solution of 70% ethanol for 7 days. Tissues were then embedded in paraffin, sectioned, and stained with hematoxylin and eosin. Tissues were examined and photographed by a veterinary pathologist experienced in mouse pathology.
Tissue processing and immunostaining for flow cytometry analysis. Airway cells were obtained by bronchoalveolar lavage (BAL) as previously described (10) . Cells were recovered from the BAL fluid by centrifugation. Following lavage, lung digestion was performed as previously described (9) . Briefly, lungs were minced and digested in Hanks' balanced salt solution (HBSS) containing 2.5 mg/ml collagenase, 10 U/ml DNase, and 10 g/ml soybean trypsin inhibitor (all reagents from Sigma-Aldrich, St. Louis, MO). After digestion, cells were triturated through an 18-gauge needle and passed through a 70-m cell strainer (BD Biosciences). Red blood cells were lysed by using ammonium chloride, and cells were washed twice in HBSS, immunostained, and then stored on ice until analysis. All cells were resuspended in fluorescence-activated cell sorter (FACS) buffer (PBS with 2% fetal bovine serum [FBS] and 0.05% sodium azide) before immunolabeling and flow cytometric analysis.
Directly conjugated antibodies for flow cytometry were purchased from eBioscience (San Diego, CA) or BD Biosciences (San Jose, CA Intracellular cytokine staining. Intracellular cytokine staining was performed as described previously (8) . Lungs were minced and digested in HBSS containing 0.4 mg/ml collagenase (Liberase TL; Roche, Indianapolis, IN) and 10 g/ml DNase (Sigma-Aldrich) for 30 min at 37°C. After digestion, cells were triturated through an 18-gauge needle and passed through a 70-m cell strainer (BD Biosciences), and red blood cells were lysed by using ammonium chloride. Following digestion, lung cells were cultured at 37°C with 5% CO 2 for 4 h in RPMI 1640 medium (Invitrogen) containing 10% fetal bovine serum (Gemini Bio-Products, West Sacramento, CA), 2 mM L-glutamine (Invitrogen), 0.1 mM nonessential amino acids (Invitrogen), 0.075% sodium bicarbonate (EMD Science, Gibbstown, NJ), 100 units/ml penicillin and 100 g/ml streptomycin (Invitrogen), 50 M 2-mercaptoethanol (Invitrogen), and 10 g/ml brefeldin A (BioLegend, San Diego, CA). Cells were washed in FACS buffer and resuspended in FACS block to prevent nonspecific staining. Cells were surface immunostained for 30 min at room temperature. In addition to the surface antibodies described above, anti-CD11c (APC conjugated; clone N418), anti-F4/80 (APC conjugated; clone BM8), anti-CD3 (APC conjugated; clone 145-2C11), and anti-CD4 (FITC conjugated; clone GK1.5) antibodies were purchased from eBioscience. Anti-CD45 antibody (Pacific orange conjugated; clone 30-F11) was purchased from Invitrogen, and anti-CD11b antibody (Alexa 700 conjugated; clone M1/70) was purchased from BioLegend. For the detection of biotinylated antibodies, cells were washed in FACS buffer and incubated with streptavidin peridinin chlorophyll protein (PerCP) (BD Biosciences) for 20 min at room temperature. Next, cells were washed with FACS buffer, resuspended in fixation-permeabilization buffer (eBioscience), and incubated at 4°C overnight. Cells were washed in permeabilization buffer (eBioscience) and resuspended in anticytokine antibodies. Anti-interleukin-12(p40/p70) [IL-12(p40/p70)] (PE conjugated; clone C15.6), anti-IFN-␥ (PE conjugated; clone XMG1.2), and rat IgG1 isotype (PE conjugated; clone R3-34) antibodies were obtained from BD Biosciences, and anti-TNF-␣ (PE conjugated; clone MP6-XT22) and rat IgG1 isotype (PE conjugated; clone eBRG1) antibodies were obtained from eBioscience. Next, cells were washed in permeabilization buffer and then washed in FACS buffer. Finally, cells were fixed in 1% paraformaldehyde for 1 h at 4°C, washed, and stored in FACS buffer until analysis. Flow cytometry was performed, and data were analyzed as described above. Cell populations were differentiated as described above. Additionally, F4/80 macrophages were defined as CD45 ϩ /F4/80 ϩ .
Assessment of cytokine production in plasma and organ homogenates. Plasma was collected in tubes coated with EDTA (BD Biosciences, San Jose, CA). Plasma was isolated from the blood by the centrifugation of Microtainer tubes at 10,000 ϫ g for 5 min at 4°C. Plasma was sterile filtered and frozen at Ϫ80°C until analysis. Lung, liver, and spleen tissues were processed as described above for the determination of the bacterial burden. Half of each organ was placed into 5 ml PBS and homogenized on the Stomacher 80 Biomaster instrument (Seward). The homogenate was centrifuged at 3,000 ϫ g for 15 min at 4°C, and supernatants were sterile filtered and frozen at Ϫ80°C until analysis.
Plasma and organ homogenates from wild-type and MyD88 Ϫ/Ϫ mice were assayed for the production of CCL2 (MCP-1), IFN-␥, TNF-␣, IL-6, and IL-12p70 by using a cytometric bead array (CBA) (BD Biosciences). Concentrations of CXCL1 (KC) were measured by using a commercially available enzyme-linked immunosorbent assay (ELISA) (DuoSet kit; R&D Systems, Minneapolis, MN) according to the manufacturer's directions. Data acquisition from CBA experiments was performed by using a FACScan flow cytometer and Cell Quest software (BD Biosciences). Analysis of CBA data was performed by using FlowJo software (Tree Star, Ashland, OR). For ELISAs, absorbance readings were determined by using a Multiskan Ascent ELISA plate reader and Ascent software (Thermo Scientific, Waltham, MA).
In vivo treatment with recombinant IFN-␥. MyD88 Ϫ/Ϫ mice were injected i.p. with either 1 ϫ 10 5 units of recombinant murine IFN-␥ (Peprotech, Rocky Hill, NJ) or diluent (PBS plus 0.1% bovine serum albumin [BSA]). IFN-␥ treatments were initiated at the time of infection and continued once daily for 5 days following infection. This treatment protocol was adapted from a protocol used previously for a Salmonella infection model (17) .
Statistical analysis. Statistical analyses were performed by using Prism 5.0 software (Graph Pad, La Jolla, CA). Survival times were analyzed by Kaplan-Meier analysis, followed by the log rank test. Analyses between two groups were performed by using a two-tailed Student t test. Comparisons between 3 or more groups were performed by using oneway analysis of variance (ANOVA) followed by Tukey's multiple-means test. Correlation analysis of bacterial burden and cytokine production was performed by using Pearson's correlation coefficient. Differences were considered statistically significant at a P value of Ͻ0.05.
RESULTS

MyD88
؊/؊ mice are highly susceptible to Burkholderia mallei infection. Previous studies have revealed that MyD88 signaling plays very different roles in protective immunity from infection with different Burkholderia species. For example, MyD88-dependent immune responses were found previously to be detrimental in the host response to B. cenocepacia infection, whereas MyD88 was critical for protective immunity against infection with B. pseudomallei and B. thailandensis (30, 33, 36) . Thus, it was unclear based on the published literature exactly what role MyD88 signaling might play in the innate immune response to acute pneumonic infection with B. mallei.
Therefore, wild-type C57BL/6 mice and MyD88 Ϫ/Ϫ mice on the C57BL/6 background (n ϭ 5 mice per group) were inoculated with a low i.n. challenge dose of B. mallei (0.5 LD 50 ; approximately 500 CFU B. mallei). Infected wild-type mice all survived to at least day 60, whereas MyD88 Ϫ/Ϫ mice were euthanized at an average of 3.5 days following challenge (Fig. 1) .
TLR2 signaling increases susceptibility of mice to lethal B. mallei infection. Previous studies indicated that TLR2 signaling actually increases the susceptibility of mice to B. pseudomallei and B. thailandensis infection (33, 35) . Therefore, we conducted experiments with TLR2 Ϫ/Ϫ mice to elucidate the role of TLR2 in protection from B. mallei infection. Wild-type and TLR2 Ϫ/Ϫ mice on the C57BL/6 background were infected with an experimentally determined LD 100 (3 ϫ 10 3 CFU; 4 LD 50 ) of B. mallei, delivered i.n. As reported previously, following B. pseudomallei or B. thailandensis infection, we found that TLR2 Ϫ/Ϫ mice were resistant to infection with B. mallei compared to wild-type mice (Fig. 2) (33, 35) . Protection could, however, be overcome by challenge with a higher dose of B. mallei. For example, when TLR2 Ϫ/Ϫ mice were challenged with 4 ϫ 10 3 CFU B. mallei, survival was reduced to 60% (data not shown). In addition, bacterial burdens were determined for wild-type mice (n ϭ 2) and TLR2 Ϫ/Ϫ mice (n ϭ 7) surviving acute disease. At day 30 or 60 following i.n. infection, we found that TLR2 Ϫ/Ϫ mice had significantly fewer bacteria in the Wild-type and MyD88 Ϫ/Ϫ mice (n ϭ 5 per group) were infected intranasally (i.n.) with 500 CFU B. mallei. Mice were monitored for survival and euthanized upon reaching a predetermined endpoint. Statistical differences were determined by using Kaplan-Meier curves and log rank analysis. Data are representative of two independent experiments. spleen (P ϭ 0.03) than wild-type mice (data not shown). In addition, there were no significant differences in bacterial counts in the blood (P ϭ 0.50), and bacterial burdens in the lung and liver were below the limit of detection for all mice (data not shown). Therefore, we concluded that TLR2 Ϫ/Ϫ mice not only were resistant to acute pneumonic infection but also were protected from the development of chronic disease.
TLR4 does not regulate resistance to pulmonary infection with B. mallei. TLR4 is a key regulator of innate immune responses to Gram-negative bacterial infections (4, 12, 31) . A recent study found that TLR4 expression did not regulate susceptibility to B. pseudomallei infection (35) . To determine whether TLR4 was required for protection from B. mallei challenge, wild-type and TLR4 Ϫ/Ϫ mice (n ϭ 5 per group) were inoculated with a low-dose i.n. challenge of 500 CFU of B. mallei. We observed that TLR4 Ϫ/Ϫ mice were not more susceptible to B. mallei infection than wildtype mice (Fig. 2) . Therefore, wild-type and TLR4 Ϫ/Ϫ mice were next subjected to a high-dose challenge with B. mallei (3 ϫ 10 3 CFU; ϳ4 LD 50 ). We found here also that TLR4 Ϫ/Ϫ mice were not more or less susceptible to B. mallei infection than wild-type animals (P ϭ 0.42) (data not shown). Quantification of bacterial burden in surviving wild-type mice (n ϭ 5) and TLR4 Ϫ/Ϫ mice (n ϭ 6) 30 days after i.n. infection revealed that chronic infection developed equivalently in wild-type and TLR4 Ϫ/Ϫ mice (data not shown). For example, bacteria were undetectable in the lung. In the liver, none of the wild-type mice were colonized, while 1 of 6 TLR4 Ϫ/Ϫ mice had a liver titer of 250 CFU/organ. There were no differences in bacterial burden observed for the spleen (P ϭ 0.87). Therefore, we concluded that TLR4 signaling did not regulate protective immunity following pulmonary challenge with B. mallei in mice.
MyD88 ؊/؊ mice have increased pulmonary and systemic bacterial burdens associated with lung and liver pathology. The above-described experiments indicated that MyD88 Ϫ/Ϫ mice were highly susceptible to B. mallei infection. Therefore, we next assessed bacterial burdens in MyD88 Ϫ/Ϫ mice at several different time points following infection. Wild-type and MyD88 Ϫ/Ϫ mice (n ϭ 5 per group) were infected with a low-dose challenge of 500 CFU B. mallei delivered i.n. Mice were then euthanized at 24, 48, or 72 h after challenge. At each time point, bacterial burdens in blood, lung, liver, and spleen homogenates were determined. MyD88 Ϫ/Ϫ mice had significantly increased bacterial burdens in all organs at all time points after infection compared to wild-type mice (Fig. 3) .
Next, organ injury in response to B. mallei infection in wildtype and MyD88 Ϫ/Ϫ mice was investigated by using histopathology. Wild-type and MyD88 Ϫ/Ϫ mice (n ϭ 5 per group) were euthanized on day 3.5 after infection with 500 CFU i.n. Lung and liver tissues were fixed and routinely processed for microscopic examination (Fig. 4) . Inflammatory responses in the lungs of MyD88 Ϫ/Ϫ mice were more severe than in those in the lungs of wild-type mice. However, the pathological changes observed for the lungs of MyD88 Ϫ/Ϫ mice were notably milder than the lesions previously observed for other strains of mice that are highly susceptible to B. mallei infection, e.g., CCR2 Ϫ/Ϫ or IFN-␥ Ϫ/Ϫ mice (10) (data not shown). In addition, the livers of wild-type mice B. mallei i.n. Survival was monitored, and mice were euthanized upon reaching a predetermined endpoint. Statistical differences were determined by using Kaplan-Meier curves and log rank analysis. Data are representative of two independent experiments. (B) Wild-type and C57BL/10ScNJ mice containing a natural deletion of TLR4 (n ϭ 5 per group) were infected i.n. with 500 CFU B. mallei. Survival was monitored, and mice were euthanized upon reaching a predetermined endpoint. Statistical differences were determined by using Kaplan-Meier curves and log rank analysis. Statistically similar results (P ϭ 0.42) were obtained in a separate experiment where wild-type and TLR4 Ϫ/Ϫ mice were challenged with 3 ϫ 10 3 CFU B. mallei i.n.
FIG 3
Increased bacterial burden in MyD88 Ϫ/Ϫ mice following low-dose respiratory B. mallei challenge. Wild-type and MyD88 Ϫ/Ϫ mice were challenged with 500 CFU B. mallei i.n. Wild-type and MyD88 Ϫ/Ϫ mice (n ϭ 3 to 5 per group) were euthanized at 24, 48, or 72 h postinfection, and the bacterial burdens in blood, lung, liver, and spleen were determined as described in Materials and Methods. Data are expressed as mean log 10 CFU/ml Ϯ standard errors of the means (SEM) for blood and mean log 10 CFU/organ Ϯ SEM for lung, liver, and spleen. Statistical differences between wild-type and MyD88 Ϫ/Ϫ mice at each time point were determined by Student's two-tailed t test ‫,ءء(‬ P Ͻ 0.01; ‫,ءءء‬ P Ͻ 0.001). Data are representative of two independent experiments. had small resolving lesions, whereas the lesions in MyD88 Ϫ/Ϫ mice were multifocal to coalescing and characterized by widespread hepatocyte necrosis and leukocyte infiltration (Fig. 4) . In contrast to the lung pathology, the liver pathology in MyD88 Ϫ/Ϫ mice was much more severe than the liver pathology previously seen for CCR2 Ϫ/Ϫ or IFN-␥ Ϫ/Ϫ mice (10) (data not shown). A comparison of bacterial burdens between MyD88 Ϫ/Ϫ , CCR2 Ϫ/Ϫ , and IFN-␥ Ϫ/Ϫ mice revealed that IFN-␥ Ϫ/Ϫ mice had significantly higher bacterial burdens in both the lung and liver than MyD88 Ϫ/Ϫ mice, while no significant differences were observed between MyD88 Ϫ/Ϫ and CCR2 Ϫ/Ϫ mice (data not shown). Therefore, we concluded that the increased lung pathology observed for IFN-␥ Ϫ/Ϫ mice compared to MyD88 Ϫ/Ϫ mice may be due to an increased bacterial burden in IFN-␥ Ϫ/Ϫ mice. However, the dramatic increases in liver pathology observed for MyD88 Ϫ/Ϫ mice appeared to be relatively independent of the hepatic bacterial burden, as CCR2 Ϫ/Ϫ mice had hepatic bacterial burdens equivalent to those of MyD88 Ϫ/Ϫ mice yet exhibited minimal hepatic pathology (10) (data not shown).
Cellular recruitment to the lung is impaired in MyD88 ؊/؊ mice. Previous studies reported that neutrophils were critical for the control of B. pseudomallei infection (8) . In contrast, we found instead that monocytes were critical for the control of B. mallei infection, based on the fact that CCR2 Ϫ/Ϫ mice were highly susceptible to infection (10) . Therefore, in the present study, we investigated the effects of TLR signaling on chemokine production and monocyte recruitment to the lungs of mice following B. mallei inoculation. Chemokine concentrations in lung homogenates and plasma from wild-type and MyD88 Ϫ/Ϫ mice (n ϭ 5 per group) were assessed 24 h after i.n. inoculation with 500 CFU B. mallei. The levels of production of both CCL2 (MCP-1) and CXCL1 (KC) were significantly reduced in MyD88 Ϫ/Ϫ mice compared to those of WT animals (Fig. 5) .
Twenty-four hours after inoculation, airway cells were collected by BAL and lung cells were obtained by enzymatic digestion and examined by flow cytometry. In both the airways and lung tissues of MyD88 Ϫ/Ϫ mice, there were significantly reduced numbers of inflammatory cells compared to those of wild-type mice. Notably, the numbers of CD11c ϩ CD11b ϩ DCs, Ly6C hi inflammatory monocytes, and neutrophils were significantly lower in both the airways and lung tissues of infected MyD88 Ϫ/Ϫ mice (Fig.  6 ). The lack of monocyte, DC, and neutrophil recruitment was particularly pronounced in the airways. The NK cell and CD4 ϩ T cell populations in lung tissues were not different in MyD88 Ϫ/Ϫ versus wild-type mice. However, MyD88 Ϫ/Ϫ mice had increased numbers of CD8 ϩ T cells (data not shown) and alveolar macrophages in the lungs (Fig. 6) . Thus, we concluded that the recruitment of key innate immune effector cells, especially inflammatory DCs, inflammatory monocytes, and neutrophils, was MyD88 dependent early after pulmonary infection with B. mallei.
Cytokine production by immune effector cells in the lungs in response to B. mallei infection. Next, we conducted intracellular cytokine production studies to identify the cellular sources of key protective cytokines in the lungs early after B. mallei infection. Wild-type mice (n ϭ 5) were inoculated with 10 4 CFU B. mallei i.n. and euthanized 48 h after infection. Lung tissue was harvested and processed for the detection of intracellular cytokine production as described in Materials and Methods. Cell types producing IL-12, IFN-␥, and TNF-␣ were investigated (Fig. 7) . The major cell type producing IL-12 in the lung following B. mallei infection was found to be a population of CD11b ϩ CD11c ϩ DCs. Smaller amounts of IL-12 were also produced by inflammatory monocytes wild-type and MyD88 Ϫ/Ϫ mice. Mice (n ϭ 5 per group) were subjected to i.n. challenge with 500 CFU B. mallei, and organs were collected for histological examination 72 h later. Representative images from the lungs (top row, ϫ20 magnification) and livers (bottom row, ϫ100 magnification) of infected wildtype and MyD88 Ϫ/Ϫ mice are presented.
FIG 5
Chemokine production following low-dose B. mallei challenge. Wildtype and MyD88 Ϫ/Ϫ mice (n ϭ 5 per group) were infected i.n. with 500 CFU B. mallei. Twenty-four hours after infection, mice were euthanized, and chemokine levels in lung homogenates and plasma were determined as described in Materials and Methods. Data are presented as individual values, with bars representing the mean concentrations for each group. Statistical differences between wild-type and MyD88 Ϫ/Ϫ mice were determined by a Student twotailed t test ‫,ء(‬ P Ͻ 0.05; ‫,ءء‬ P Ͻ 0.01; ‫,ءءء‬ P Ͻ 0.001). Data are representative of two independent experiments. and resident alveolar macrophages. The majority of IFN-␥ was produced by NK cells in the lungs, while small numbers of T cells also expressed IFN-␥.
Unexpectedly, a large population of IFN-␥ ϩ cells that did not express NK cell or T cell markers (i.e., NK1.1 Ϫ /CD3 Ϫ ) was also observed (data not shown). We found that within this population of cells, there were IFN-␥ ϩ DCs, monocytes, and neutrophils ( Fig.  7 and data not shown) . Previous studies have demonstrated that multiple myeloid cell types can produce IFN-␥ following stimulation with IL-12 (3, 19) . However, the remaining IFN-␥ ϩ cells were not identified, although we did note that they were not ␥␦T cells (data not shown).
The cellular source of TNF-␣ production was investigated next. We found that neutrophils were the major cellular source of TNF-␣ production in the lungs shortly after B. mallei infection (Fig. 7) . This finding differs from results obtained in a previously reported B. pseudomallei model, where monocytes were identified as the major source of TNF-␣ production (8) . We also observed that some monocytes, dendritic cells, and alveolar macrophages expressed TNF-␣.
MyD88-dependent cytokine production following B. mallei infection. Cytokine concentrations in lung tissues and plasma were investigated next in wild-type and MyD88 Ϫ/Ϫ mice following i.n. challenge with 500 CFU B. mallei. Mice (n ϭ 5) were euthanized 24, 48, or 72 h after infection, and cytokine concentrations were measured in lung homogenate and plasma as described in Materials and Methods. Compared to WT mice, MyD88 Ϫ/Ϫ mice had significantly reduced concentrations of TNF-␣ in the lung and plasma at 24 h after infection, whereas concentrations were not different at later time points (Fig. 8) . IL-12 concentrations in lung tissues were below the limit of detection for both groups of animals (data not shown). IL-6 production in the lungs was significantly reduced in MyD88 Ϫ/Ϫ mice compared to WT animals (data not shown). Remarkably, we found that MyD88 Ϫ/Ϫ mice were unable to produce detectable IFN-␥ in lung tissues or in the circulation at any time point examined (Fig. 8) . Thus, we concluded that the production of IFN-␥ following pulmonary infection with B. mallei was completely dependent on MyD88 signaling, whereas the production of other key proinflammatory cytokines (TNF and IL-6) was only partially MyD88 dependent.
The fact that bacterial burdens were very different in the lungs of MyD88 Ϫ/Ϫ and WT mice could confound the interpretation of cytokine response data. Therefore, to eliminate this potential bias, we increased the challenge dose in WT animals to achieve equivalent tissue bacterial burdens in both WT and MyD88 Ϫ/Ϫ animals (Fig. 8B) . Even after achieving equivalent bacterial burdens, we noted that the levels of production of IFN-␥, TNF-␣, and IL-6 were all significantly reduced in MyD88 Ϫ/Ϫ mice compared to wild-type animals ( Fig. 8C and data not shown) . Interestingly, plasma concentrations of TNF-␣, but not IL-6 or IFN-␥, were increased in MyD88 Ϫ/Ϫ mice at 72 h compared to wild-type mice, with equivalent tissue bacterial burdens (Fig. 8C and data not  shown) . Thus, MyD88 Ϫ/Ϫ mice appeared to have a compensatory mechanism for the systemic production of TNF-␣ in response to i.n. B. mallei infection.
Since adjusting bacterial challenge doses to achieve equal bacterial burdens is time-consuming and expensive, we investigated whether it was possible to adjust cytokine concentrations simply based on the bacterial burden. The validity of this assumption was explored by determining whether there was a significant correla- tion between the cytokine concentration and bacterial burden at different bacterial burdens. Bacterial burdens and cytokine concentrations were measured in the lung (n ϭ 60) and plasma (n ϭ 18) of wild-type mice infected with either 500 or 10 4 CFU B. mallei. For the lung, we found significant correlations with bacterial burden for CCL2, CXCL1, IL-6, and TNF-␣ concentrations (P Ͻ 0.001). However, a correlation with IFN-␥ concentrations was not observed (P ϭ 0.28). Cytokine production from wild-type and MyD88 Ϫ/Ϫ mice infected with 500 CFU i.n. (Fig. 8A) was mathematically normalized to the bacterial burden (Fig. 8E) . The normalization of TNF-␣ and IL-6 in the lung produced results consistent with results obtained following a high-dose infection (Fig.  8C and data not shown) . These results demonstrate that the increased production of TNF-␣ seen at 72 h (Fig. 8A) was mostly due to an increased bacterial burden in MyD88 Ϫ/Ϫ mice. In contrast, plasma concentrations did not correlate with bacterial burden for any of the cytokines investigated in this study (Fig. 8D and  data not shown) . Therefore, in the lung, but not the blood, the normalization of cytokine concentrations to the bacterial burden may be valid for the evaluation of most inflammatory cytokines but not IFN-␥.
In summary, B. mallei infection induced the early production of IFN-␥, TNF-␣, and IL-6 in both the lung and plasma of wildtype animals, whereas concentrations were significantly reduced in MyD88 Ϫ/Ϫ mice. However, MyD88 Ϫ/Ϫ mice had increased levels of production of TNF-␣ in the plasma at 72 h, which was independent of the bacterial burden (Fig. 8C) . MyD88 Ϫ/Ϫ mice were, however, incapable of producing IFN-␥ at any time point regardless of the bacterial burden.
Recombinant IFN-␥ treatment protects MyD88 ؊/؊ mice. Therefore, we focused our attention next on the IFN-␥ production defect in MyD88 Ϫ/Ϫ mice and whether IFN-␥ was indeed the key cytokine required for MyD88-dependent protection from B. mallei infection. To address this question, MyD88 Ϫ/Ϫ mice were treated with recombinant murine IFN-␥ immediately after B. mallei infection. The mice were treated once daily with 10 5 units of recombinant IFN-␥ (rIFN-␥) administered intraperitoneally (i.p.) as described previously for a mouse Salmonella infection model (17) . Mice (n ϭ 5) were treated with rIFN-␥ at the time of infection and then once daily for 5 days, while a separate group of control MyD88 Ϫ/Ϫ mice (n ϭ 5) received i.p. injections of diluent. Treatment with rIFN-␥ provided significant, though not complete, protection against respiratory B. mallei infection compared to MyD88 Ϫ/Ϫ mice receiving diluent (Fig. 9) . Additionally, while 80% of MyD88 Ϫ/Ϫ mice treated with rIFN-␥ cleared bacteria from their lungs, all mice ultimately developed disseminated infection in the spleen and liver (data not shown).
DISCUSSION
In the present study, the role of MyD88 signaling in generating protective immunity against pulmonary challenge with B. mallei was investigated in order to gain a better understanding of the role of innate immunity in controlling pulmonary infection with this important pathogen. Notably, we found that MyD88 Ϫ/Ϫ mice were highly susceptible to infection with even very low intranasally delivered doses of B. mallei. Along with an inability to control bacterial replication in the lungs, inflammatory responses in the lungs of MyD88 Ϫ/Ϫ mice were significantly attenuated. For example, MyD88 Ϫ/Ϫ mice were unable to recruit inflammatory monocytes, myeloid dendritic cells, or neutrophils to the lungs. In contrast, no differences in pulmonary NK or CD4 ϩ T cell populations were observed, while numbers of CD8 ϩ T cells were increased in MyD88 Ϫ/Ϫ mice. Cytokine analysis revealed that MyD88 Ϫ/Ϫ mice were completely unable to produce IFN-␥, while the levels of production of TNF-␣ and IL-6 were reduced only at early time points. Remarkably, despite the large number of immune defects observed for MyD88 Ϫ/Ϫ mice following B. mallei infection, the treatment of MyD88 Ϫ/Ϫ mice with only rIFN-␥ was able to significantly reverse their susceptibility to B. mallei infection.
Some immune responses in MyD88 Ϫ/Ϫ mice following B. mallei infection were similar to those observed previously for MyD88 Ϫ/Ϫ mice infected with B. pseudomallei (36) . For example, neutrophil recruitment was reduced in both infection models in MyD88 Ϫ/Ϫ mice. However, MyD88 Ϫ/Ϫ mice infected with B. mallei also exhibited significant defects in monocyte recruitment, which was not observed previously for MyD88 Ϫ/Ϫ mice infected with B. pseudomallei or B. thailandensis (33, 36) . The reasons for this difference are unclear, since MyD88 Ϫ/Ϫ mice infected with any of these three Burkholderia species produce significantly less CCL2 than wild-type animals (33, 36) .
Other notable differences between B. mallei-and B. pseudomalleiinfected mice include differences in cell types producing TNF-␣. We found that neutrophils were the major cellular source of TNF-␣ production in the lungs following B. mallei infection, whereas previous studies found that monocytes were the primary source of TNF-␣ production following B. pseudomallei infection (8) . The reasons for these differences are unclear but could be related to differences in the bacterial envelope (e.g., lipopolysaccharide [LPS] or capsule) or to the bacterial burden or the timing of sampling. In agreement with data from previous studies of B. mallei and B. pseudomallei, IFN-␥ was produced mainly by NK cells (8, 14, 23) .
Our previous studies with CCR2 Ϫ/Ϫ mice indicated that IFN-␥ was critical for protection against B. mallei infection (10) . Therefore, the production of IL-12, which is the key molecule regulating the NK cell production of IFN-␥, was investigated following B. mallei infection. We found that IL-12 in the lungs was produced largely by DCs and monocytes. Since the recruitment of both DCs and monocytes to the lungs was significantly impaired in MyD88 Ϫ/Ϫ mice, we postulate that the defect in IFN-␥ production observed for the lungs of MyD88 Ϫ/Ϫ mice was due to the lack of local IL-12 production. Our results are in accordance with previous findings from a Listeria monocytogenes infection model, which also identified monocyte-derived DCs as the major cellular source of IL-12. Additionally, IL-12 production by DCs following Listeria monocytogenes infection was found previously to be dependent on MyD88 signaling (37) .
IFN-␥ is known to be critical for the immune response to B. mallei infection, and inflammatory monocytes appear to be critical for the production of IFN-␥ (10, 23). Monocytes were also found to be critical for protection following intravenous inoculation with Francisella tularensis, where MyD88 Ϫ/Ϫ , IFN-␥R Ϫ/Ϫ , and CCR2 Ϫ/Ϫ mice all had defects in monocyte recruitment to the spleen (20) . Similar to the current study, IFN-␥ production following intravenous (i.v.) F. tularensis infection was also found to be MyD88 dependent. Signaling through the IFN-␥ receptor (IFN-␥R) was necessary for CCL2 production, and CCL2 production was necessary for monocyte recruitment. A similar TLRdependent signaling circuit may be occurring following B. mallei infection of MyD88 Ϫ/Ϫ mice.
Important differences were also identified, however, including the fact that in the B. mallei infection model, TNF-␣ production remained intact in CCR2 Ϫ/Ϫ mice despite reduced monocyte recruitment to the lung. Neutrophils were the major source of TNF-␣ production in B. mallei-infected mice, and TNF production was at least partially MyD88 independent. Additionally, although CCR2 Ϫ/Ϫ mice retained the ability to signal through MyD88 and produce IFN-␥ in response to TLR3-activating ligands, CCR2 Ϫ/Ϫ mice produced less IFN-␥ following B. mallei infection (10) . These results demonstrate that additional signals, in addition to MyD88, are necessary for the production of IFN-␥ following infection with B. mallei.
Although the administration of exogenous IFN-␥ was sufficient to induce a partial but significant protection of MyD88 Ϫ/Ϫ mice from acute disease following B. mallei infection, the protection was not complete. This finding suggests that other cytokines may be necessary for full protection. Indeed, the levels of production of a number of other cytokines were significantly reduced in IFN-␥ (rIFN-␥) or diluent (PBS plus 0.1% BSA) (n ϭ 5 per group) as described in Materials and Methods. Mice were challenged with 500 CFU B. mallei i.n. Survival was monitored, and mice were euthanized upon reaching a predetermined endpoint. Statistical differences were determined by using Kaplan-Meier curves and log rank analysis. Data were pooled from two independent experiments.
B. mallei-infected MyD88 Ϫ/Ϫ mice. For example, the levels of production of TNF-␣, CCL2, CXCL1, and IL-6 were all significantly reduced at 24 h postinfection in the lungs of MyD88 Ϫ/Ϫ mice compared to wild-type mice (Fig. 5 and 8 and data not shown). Similar to previous studies with a B. thailandensis model of pulmonary infection, we found that MyD88-independent mechanisms resulted in increased cytokine production in MyD88 Ϫ/Ϫ mice 72 h after infection, although the extremely high bacterial burdens in MyD88 Ϫ/Ϫ mice made the interpretation of cytokine production difficult (33) (Fig. 3) .
It was also noted in this study that MyD88 Ϫ/Ϫ mice infected with B. mallei developed much more severe hepatic necrosis than wild-type animals (Fig. 4) . A similar effect was observed previously for MyD88 Ϫ/Ϫ mice infected with B. pseudomallei (36) . It is possible that the high bacterial burdens in the livers of MyD88 Ϫ/Ϫ mice may account for this dramatic liver pathology. However, previous studies from our laboratory demonstrated that B. mallei infection of CCR2 Ϫ/Ϫ or IFN-␥ Ϫ/Ϫ mice resulted in equivalent or increased liver bacterial burdens compared to those of MyD88 Ϫ/Ϫ mice (data not shown), yet neither CCR2 Ϫ/Ϫ nor IFN-␥ Ϫ/Ϫ mice developed the severe liver pathology observed for MyD88 Ϫ/Ϫ mice (data not shown) (10, 11) . Thus, we propose that an increased systemic production of TNF-␣ in MyD88 Ϫ/Ϫ mice may be one explanation for the accentuated liver pathology observed in this study, likely triggered by LPS released from dead or dying bacteria (Fig. 8) (2) . Moreover, the adverse effects of LPS and TNF-␣ on the liver appear to be magnified by the lack of MyD88 signaling. For example, MyD88 Ϫ/Ϫ mice are known to have defects in liver regeneration (26) . Additional defects in MyD88 Ϫ/Ϫ mice may also contribute to liver damage, as other cytokines in addition to TNF-␣ are known to elicit liver damage and suppress effective regeneration (5, 6, 25, 28) .
In summary, we report here that MyD88 is a critical molecule required for effective innate immunity against pulmonary infection with B. mallei. Interestingly, the lack of TLR2 or TLR4 signaling did not recapitulate the effects of an MyD88 deficiency in our studies. As TLR9 signaling was also reported not to play a role in protection from B. pseudomallei infection, mice lacking individual TLRs do not appear to be as susceptible to Burkholderia infection as MyD88 Ϫ/Ϫ mice (33, 35, 36) . These results suggest that multiple TLRs must be concurrently inactive to reproduce the MyD88 phenotype. Alternatively, TLR-independent but MyD88-dependent signaling through the IL-1 receptor (IL-1R) or IL-18R signaling pathways may be necessary for inducing full protection against Burkholderia infection. The major immune defects in MyD88 Ϫ/Ϫ mice appear to be related to the decreased recruitment of inflammatory DCs and monocytes to the lungs, since these are the primary cellular sources of IL-12 production, which in turn regulates IFN-␥ production by pulmonary NK cells. This hypothesis is bolstered by the fact that simply replacing the missing IFN-␥ by the administration of rIFN-␥ can largely restore effective short-term immunity to B. mallei infection. These findings suggest that strategies to enhance DC or monocyte recruitment to the lungs, as well as local IL-12 production, could be effective countermeasures for B. mallei infection. Indeed, our previous studies of mucosally delivered immunotherapy for Burkholderia infection suggest that this approach can efficiently protect animals from pulmonary challenge (11) .
